Tobacco Documents Online

WINTER 1982 The Scientific Advisory Committee Commonly referred to as SAC, the Scientific Advi- sory Committee of the Runyon-Winchell Cancer Fund has played a vital role in nuturing young scientists in cancer research for more than three decades. Prominent scientists from across the nation have generously af- forded us their talent, dedication, and time creating the prestigious aura which typifies the Fund today. Presently, SAC is comprised of these fifteen eminent doctors and scientists who travel to New York three times a year to review postdoctoral fellowship grant applications: John Abelson, Ph.D., University of California, San Diego Jerome DeCosse, M.D., Sloan-Kettering Institute Darrell Dbyle, Ph.D., Roswell Park Memorial Institute Malcolm L. Gefter, Ph.D., Massachusetts Institute of Technology Victor Ginsburg, Ph.D., National Institutes of Health Irving Goldberg, IvI.D., Harvard Medical School Arthur P. Grollman, M.D., SUNY at Stony•Brook Evan Hersh, M.D.. M.D. Anderson Hospital David Hiesh, Ph.D., University of Colorado, Boulder Michael E. Lamm, M.D., Case Vkestern Reserve University George luliller, Jr., M.D., Yale University School of Medicine Dan Rifkyn, Ph.D., New York Unversity Joseph Simone, M.D., St. Jude Children's Research Hospitel Bill Sugdkn, Ph.D., University of Wisconsin Paul V. VVi;wlley, M.D., FACP, Georgetown University Hospital Each member has been recommended by SAC and approved by the Board of Directors of the Fund for membership. Their tertn is four years, which includes participation in a maximum of twelve review sessions. In an average year these professionals peruse 600 appli- cations; this is a feat in i:self, but also an addition to their institutional obligations and research programs. Applications are evaluated for the qualifications, ex- perience, and productivity of the candidate and sponsor, the merit of the research proposal and the training envi- fContlnued on pugr 4) ~atta THIRD ISSUE PROFILE: Dr. Gerald P. Murphy Dk: Gerald P. Murphy, chautnan of the executive committee of the Runyon-Winchell Cancer Fund"s Board of Direc- tors, has played an ex- tr empty active role in as- sistiri the Fund in its re- cent eriod of expansion. Born in Havre, Montana in 1934, Dr. Murphy graduated from Seattle University in 1955. He received his medical degree from the University of Washington and completed his residency in Surgery and Urology at The Johns Hopkins Hospital. After completing a Visit- ing Professorship in Surgery at the University of Stellen- bosch in South Africa, Dr. Murphy joined Roswell Park Memorial Institute in Buffalo in 1968. He held the aosi- tion of Chief of the DepartnAent of Urology and As- sociate Institute Director until 1970, when he was ap- pointed Institute Director. Dr. Murphy also holds posi- tions as Professor of Surgery at SUNY at Buffalo a!td Professor of Biology at Niagara University. He has served as Executive Director, of the Health Research Council of the State of New York since 1975. As director of Roswell Park Institute, a comprehen- sive tattcer center, Dr. Murphy is responsible for the management of the entire institute in all of its many facets, including research, treatment, and education. Thete are currently more than 450 cancer research inves- tigatibns in progress, in 16 basic research units. Each department is responsible for developing major research themes, which at present include experimental hema- tology, biological structure and function, micro- processor technology, SV40 studies of cell transforma- tion, metastasis, drug development, the immune re- sponse, and genetic factors 4n human disease. Among special facilities at the Institute are a crystallography center, a computercenter, animal models forexperimen- tal sutgery, recombinant DNA laboratory, and a mouse breeding facility. fConrinon•d on page SI

Dr. Shin Leaves Scientific Advisory Commiittee Dr. Seung-il Shin, Professor of Genetics at Albert Einstein College, served as a member of the Fund's Scientific Advisory Committee from 1978 until this June, when his four-year term ended. 71te Fund is most grateful for his guidance and incisive commentary in the selection of Runyon-Winchell Fellows, and will miss his contribution to the Committee. Following is Do. Shin's report c- his association with the Fund. It has been my great privilege to serve on the Fund's Scientific Advisory Committee during the last four ya:ars. Personally, it was an experience filled avith the pleasure of worki,ng with distinguished colleagues from the major research centers of this country, and with hard vuork required for evaluating the applications as criti- cally and impartially as possible. It was also artl experi- ence through which I tearned to appreciate the basic wisdom of the Fund's current policy of concentrating its available resources on nurturing the scientific develop- ment of future cancer investigators here and abroad. The history of science, teaches tis that science cannot develop confined within national boundaries; the eventual solu- tion to the cancet problem will certainly depend on the cooperative efforts of the best scientists of the world. For this reason, the Fund's admirable record in identifying and encouraging the best young minds - regardless of where the) come from and where they work -- is one that I am proud of. I received my,formal education in Korea and in the United States, amd was trained futther in the Nether- lands, England and Switzerland, before starting my re- search career in New Yotk. While I do represent a,~t extreme case, such mixtures of countries and traditions afre quite common in modern science. Initially, my re- search in New York was concerned with finding out how a cancer cell may be distinguished fiom its nornlal coun- terparts. This lea us to depend heavily on the use of a laboratory mouse mutant called "nude mouse," so named because of the complete absence of hair. A nude mouse has, an inherited immune deficiency artd thus cannot recognize the criticpl difference between its own normal body cells and other cells - such as human cancer cells - that may be grafted in it. Even though these mice can survive only undr the protective labora- tory environment, they have become a very important research aid for studies on how cells become cancerous and how the cancer cells disseminate throughout the body. More recently, my research turned to the causes of juvenile-onset diabetes. This form of diabetes usually afflicts very young children, who then have to be treated with daily administrations of insulin. It is believed that this Sype of diabetes may be an autoinunune disease, meaning that the bcdys natural defense mechanism is inappropriately turned against itself, causing tissue damage. For these studies also, the nude mouse per- forms an essential function by being our surrogate pa- tient. Students and research fe~lows from different countries have contributed to our research, and I am personally pleased that one of our fellows was supported by the J I J/ ~ i) t und for her postdoctoral training in cancer genetics. At a time when public sources of educational support arc becoming increasingly scarce, the Fund's role in insur- ing the continued flow of gifted and dedicated young scientists into caticer research is more important than ever. William Randolph Hearst. Jr. has been appoinred Honorarv National Chairman of the Runron-Winchell Cancer Fund. .t.egacies and Bequests - We' Need Your Help In 1946, Walter Winchell established the Fund in memor,v of his friend Damon Runyon. the noted writer and columnist who died of cancer. In his Sunday night radio broadcasts, Winchell appealed to the American public to help fight the disease by putting the Fund in their wills. People by the hundreds responded, and since that time, a large percentage of the Funds income has been derived from those concerned and generous listen- ers. However, since Mr. Winchells death in 1912, his appeal to remember the Fund in this manner has been lost. We ask your help in renewing this idea, and hope you will consider placing the Runyon-Winchell Cancer Fund in your will. Remember, all contributions to the Fund, including gifts made through bequests and legacies, are used it: their entirety for cancer research. No portion of a gift is ever deducted for fund-raising or administrative costs. Wfe deeply appreciate your support and interest in the work of the Fund, and thank you for your continued commitment. For information about our bequest and legacy program, please contact Doreen DeSario in our legal department, 582-5400.

Dr. Shin Leaves Scientific Advisory Committee Dr. Seung-il Shin, Professor of Genetics at Albert Einstein College, served as a member of the Fund's Scientific Advisory Committee from 1979 until this lune, when his four-year term ended. The Fund is most grateful for his guidance and incisive commentary in the selection of Runyon-Winchell Fellows, and will miss his contribution to the Committee. Following is Dr. Shin's report on his associatioti with the Fund. It has been my great privilege to serve on the Fund's Scientific Advisory Committee during the last four years. Personally, it was an experience filled with the pleasure of working with distiquished colleagues from the major research centers of this country, and with hard work required for evaluating the applications as criti- cally and impartially as possible. It was also an experi- ence through which I learned to appreciate the basic wisdom of the Fund's c>neent policy of concentrating its available resources on nurturing the scientific develop- ment of future cancer investigators here and abroad. The history of science teaches us that science cannot develop confined within national boundaries; the eventual solu- tion to the cancer problem will certainly depend on the cooperative efforts of the best scientists of the world. For this reason, the Fund S admirable record in identifying and encouraging the best yourdg minds - regardless of where they come from and wlhere they work - is one that I am proud of. I received my foraa education in ICorea and in the United States, and was trained further in the Nether- lands, England and Switzerland, before statting my re- search career in New York. While I do represent an extreme case, such miattures of countries and traditions are quite common in modern science. Initially, my re- search in New York was concerned with finding out how a cancer cell may be distinguished from its normal coun- terparts. This led us to depend heavily on the use of a laboratory mouse mutant calted "nude mouse," so named because of the complete absence of hair. A nude mouse has an inherited immune deficiency and thus cannot recognize the critical difference between its own normal body cells and other cells - such as human cancer cells - that may be grafted in it. Even though these mice can survive only under the protective labora- tory environment, they have become a very important research aid for studies on how cells become cancerous and how the cancer cells disseminate throughout the body. More recently, my research turned to the causes of juvenile-onset diabetes. This form of diabetes usually afflicts very young children, who then have to be treated with daily administrations of insulin. It is believed that this type of diabetes may be an autoimmune disease, meaning that the body's natural defense mechanism is inappropriately turned against itself, causing tissue damage. For these studies also, the nude mouse pen forms an essential function by being our surrogate pa- 6ent. Students and research fellmws from different countries have contributed to our research, and I am personally pleased that one of our fellows was supported by the Fund for her postdoctoral training in cancer genetics. At a time when public sources of educational support are becoming increasingly scarce, the Fund's role in insur- ing the continued flow of gifted and dedicated young scientists into cancer research is more important than ever. 1411lliam Randolph Hearst, Jr. has been appointed Hmtoran National Chairman of the Rum•on-~nrhell Cancer Fund. Legacies and Bequests - We Need Your Help In 1946, Walter Winchell established the Fund in memory of his friend Damon Runyon, the noted writer and columnist who died of cancer. In his Sunday night radio broadcasts, Winchell appealed to the American public to help fight the disease by putting the Fund in their wills. People by the hundreds responded, and since that time, a large percentage of the Fund's income has been derived from those concerned and generous listen- ers.. However, since Mr. Winchells death in 1972, his appeal to remember the Fund in this manner has been lost. VNe ask your help ;n renewing this idea, and hope you will consider placing the Runyon-Winchell Cancer Fund in your will. Remember, all contributions to the Fund, including gifts made through bequests and legacies, are used in their entirety for cancer research. No portion of a gift is ever deducted for fund-raising or administrative costs. U@ deeply apprc:iate your support and interest in the work of the Fund, and thank you for your con:inued commitment. For information about our bequest and legacy program, please contact Doreen DeSario in our legal department. 5B2-3400. UI

New Runyon-Winchell Fellowships Awarded Once again the Fund is proud to present a listing of the esteemed scientists recommended for Fellowships to the Board of Directors by the Scientific Advisory Conunit- tee. Carol Thummel, Ph.D., Stanford University, Regula- tion of the Ecdysone Induced Genes of Drosophila" Carol Westbrook, M.D., Ph.D., University of California, Los Angeles, "Molecular Studies of Ery- throid Potentiating Activity" Marityn Resh, Ph.D., Harvard University, "Mem- btane Insertion of the Rous Sarcoma Virus Tiansfoiming Protein" Karla Kirkegeard, Ph.D., MaS,sachusetts Instithrte of '@chnokigy, "The Mechanism of RNA Recombination in Poliovirus" Elaine Remmers, Ph.D., SUNY at Stony Brook, "Non-Inununoglobulin Associated Rearranging DNA in iLmor Cells" John Moran, Ph.D., Harvard University, "A Ra- tional Approach to the Design and Synthesis of Anti- cancer Agents" Mary Porter, Ph.D., University of Hawaii, "The Role of the Dynein ATPases in Flagellar Motility" Paul Mains, Cold Spring Harbor Laboratory, "Molecular and Genetic Mapping of the Mouse r Com- pleX " ~ Stephen Crews, Ph.D., Siardord University, "B- Lymphocyte Differentiation: Analysis at the Gene Level" Eric Phyzicky, Ph.D., California lnstitute of T>:chnologv, "In Vivo Function of the S. Cerevisiae tRNA Ligase Protein" David Anderson, Ph.D., Columbia University, "Molecular Biology of Nerve Growth Factor Receptor " Jedd Levine, M.D., Stanford University, "Regitlation of Growth and Differentiation in Mamtnary Epithelium" Elizabeth GetzoR, Ph.G., Scripps Clinic and Re- search Foundation, "Electrostatic Recognition Proc- esses Controlling the Specificity of Intermolectilar In- teracdon and Assembly" Daniel Reinberg, Ph.D., University of Colifornia, Berkeley, "Development of an in vitro Assay to Study Ii'ansposition" Myles Brmvn, M.D., Sidney Farber Cencer Insti- tute, "Functional Significance of Nucleotide Coupling and Release Prol+erties of the SVIO Large T-Atitigen" David Stern, Ph.D., Massaehusetts Institute aif'la;ch- nology, "'hattscription of Cellular Oncogene and its Progenitor" Paula Grabowski, Ph.D., MassAachusetts Inst6tute of '4chuology, "Development of an in vitro mRNA Splic- ing System" r Joseph Messiaa, Ph.D., University of Virginia, "The Role of Insulin Mediators in the Regulation of Specific mRNA Synthesis in Liver Cells" Harry Drabkin, Ph.D., University of Colorado, Detever, "Isolation and Characterization of the 8:21 Tramslocation of Acute Myelogenous Leukemia" Michael O'Donnell, Ph.D., Stanford University, "The Dissociation Mechanism of the Escherichia Coli ATP-Activated DNA Polymerase N Holoenzyme from Replicated DNA" Jinti Matttredi, Ph.D., Harvard University, "Role of the Cytoskeleton in Receptor Mediated Endocytosis" Brett'I~ler, Ph.D., University of Georgia, "Molecular Regulation of the Neurospora QA Genes" 1etesa Keng, Ph.D., Massachusetts Institute of 'Ipchnology, "Transport of Iso-l-Cytochrome c into Yeast Mitochondria" John Leigh, Ph.D., Massachusetts Institute of lkchnology, "A Genetic Study of Nodulation Mechan- isms in Rhizobium" Michael Grace, Ph.D., University of Chicago, "Biochemical Studies of Abnormal Differentiation in Huenar. Squamous Cell Carcinoma of the Lung" Robert Moreland, Ph.D., Sidney Farber Cancer In- stitute, "Transcriptional Regulation of Yeast Histone Genes" Diane Kiino, Ph.D., Frederick Cancer Research, "Genetic Analysis of Intragenic Sequences Specifying Eukaryotic Protein Membrane Insertion" Jeremy Boss, Ph.D., Harvard University, "Cloning of the HLA-D/Dr Light Chain Genes" Steve Koseiuk, Ph.D., University of Wisconsin, 'Minor Growth Kinetics During Mouse Hepatocar- cinogenesis" Joan Hooper, Ph.D., MRC-Lub, England, "Early Morphogenesis in Drosophila Embryos Studied with Monoclonal Antibodies and Cytoplasmic Transfer" RUNYON-WINCHELL CANCER FUND BOARD OF DIRECTORS • Charles A. LeMaistre, M.D. - Ptesident • Ralph T. Horgan - Vice president • Gerald P. Mutphy. M.D., D.Sc. - Chairman, Executive Conunitee Louis DeLuca - Serretaryllkasurer David Brown Helen Gurley Brown R. Lee Clark, M.D. Gordon Fawcett Wemer H. Kirsten. M.D. Irviog Kupc~net • Philio O'B. Montgomery, 1r., M.D. • W.P. t.aird Myers. M.D. Henry C. Pitot, M.D.. Ph.D. • William G. Simon. Esq. • Executfve Cotnmittee Louis DeLuca. Executive Director Suzanne Kieman and Amy Pouard, Newsletter Editors 3

Runyon-Winchell Fund Flies a Kite Most people in New York City look straight ahead when walking, (or sometimes down to avoid souvenirs from large dogs) but on Sunday, October 3rd, all eyes were raised to the heavens, where a truly spectacular show was taking place.. The sky was filled with dozens of kites of all sizes, colors, and shapes. swooping. swirl- ing, and riding gracefully on the gentle breezes that wafted over Central Park. The First Annual New York City Kite Jamboree took place in the Sheep Meadow in the park, and was a most enjoyable day for the more than 3,000 people who par- ticipated. The event, which was co-sponsored by the kite emporium, GO FLY A RlTE, was held by the Runyon-Winchell Cancer Fund to celebrate both New York City and the Sheep Meadow, which was recently completely re-sodded. In fact, the Kite Jamboree was the first large event that, the Parks Department allowed to be held in the Meadow. The winner of the "mitsr kites on a line" competirion rakes to the skies at the Kite Jamboree in Central Park. The Kite Jamboree was blessed with beautiful, sunny, and -even more imparkattt-breeay weather. Over 100 people -- participants in thr kite competi.tion - started lining up before noon to register for such categories as highest flying kite, biggest, smallest, most beautiful, and most kites on one line. As the first kites took to the air, the melodious sounds of the big bands of the 1940 S floated out to meet them. The music was provided by the Staten Island Senior Stdge Band, a group composed of the most talented performers from the Staten Island Public schools. There were several special kite demonstrations during the day, among them a fearsome performance by a thirty-foot shark kite (just when you thought it was safe to go back into the sky) and a seven-kites-in tandem exhibition by internationally renowned flier Gerard Hacqeubard. 4 Besides the participants in the various competitions, many people took to the Sheep Meadow as part of a"free fly," while others were content to lie in the soft new grass and watch the friendly invasion of the skies by the many varieties ef kiths that dotted the landscape. A kit'ee doctor, complete with "medical" bag and white coat, threaded his way through the crowds to repair tom kites. while free lessons were given to neophyte fliers at the southern end of the Meadow. At the end of the day, prizes were awarded to the winners of the kite competion. They ranged from the largest (7 feet pn diameter), the smallest, (less than one inch-atdd it flew!) and most kites on a line (fifty). The Fund looks forward to our second annual Kite Jamboree in April, and will provide you with more information on this event in our Spring newsletter. For those of you who flew with us this time, thanks! - Amy Pollard Scientific Advisory Committee fContinued from page 11 romttent available to the candidate are also considered. The process is often tiresome and tedious, but neverthe- less necessary to fairly evaluate the applications. Spmmaiies of all applications submitted for a specific deadline are forwarded to all SAC members. They select 25 proposals in their field of expertise and relay this - information to the Research Department. Aided by the designated Scientific Chairman, SAC members are as- signcd between 16-20 applications to review. Two re- viewers are assigned to an application, one as the pri- tnary reviewer and the other as a secondary reviewer. Both reviewers formulate a written critique; however, the primary reviewer describes in more detail the proj- ect, the spernsoring investigator, and the fellowsfoip can- didate. When addnessing SAC at the review session both reviewers give an oral evaluation and suggest their prior- ity rating of the application. After a general discussion each member of the review panel votes his priority score and the cycle continues. What may appear superficially to be a simplistically structured task it, otrthe contrary, a complex assignment that only a panel of experts could handle. Participation at a review session as a lay person can leave you with your ' jaw hanging. ^ It is an inspiring, stimulating, and unique experience. Some seemingly picayune detail of an experiment will elate one of the reviewers and sud- denly, a remarkable presence fills the roor.t. It is this type of e xuberamt energy that sustains these profession- als through the two-day meeting. The Scientific, Advisory Committee is a cornerstone of the Fund. We are extremely fortunate to have an association with such a fine caliber of scientists, and likewise, the future Runyon-Winchell Fellows. In closing we would like to thank SAC, and pitrticu- larly, Dts. David Hirsh and Miclaael Lamm who ate just completing their term of service. Their untiring efforts in our `.whalf have been most gratifying, and we wish them continued success in their future endeavors. - Suzanne M. Kiernan

Cancer And Our Civilization Throughout history mankind has been afflicted by a variety of diseases. Leprosy, the plague, and the "White Death" of tuberculosis have all figured prominently in the history of mankind. But today the disease which most concerns all of us and whose very name strikes fear into the hearts of most people is cancer. Cancer is many things to many people. The layman views it as a frightening and unpredictable attack on his health and well-being. The physician considers cancer as a serious disease which affects his patient; the inves- tigator studies the cancer cell and views it as the reflec- tion of one or more derangements in the biological chemistry of the living organism. The scientist or physi- cian who studies and treats neoplastic disease (cancer) sees a neoplasm as a "relatively autonomous growth of tissue." This phrase simply means that the cancer cell and all of its daughter cells do not obey the rules of the game. The autonomy of cancer is the basic defect of the cancer cell. Normal cells of our body grow in a very regulated manner and respond to internal signals known as hormones, which coordinate the functions of the billions of independent cells which make up the whole organism. Cancer cells either do not obey these signals, or they respond to them in an abnormal manner. We would never see a cancer unless it grew, but there is good rr.ason to believe that some cancercells may lie dormant without expressing themselves for many years or even throughout the life of an individual. Final'y, at our pre- sent state of knowledge we can define cancer only in a multicellular organism such as the human. Therefore, bacteria, yeast, and other single-celled organisms are not afflicted with this curse of evolution. There are many types of cancer; in fact, as many as thene are types of cells within the individual. Some neoplasms are considered benign in that they are slow- growing and do not spread to distant parts of the body (metastasize). In addition to possessing ail the proper6es of benign neoplasms, malignant neoplasms can metas- tasize. Cancer has been with us through the ages. Paleo- pathologists have shown that the dinosaurs suffered from this malady. The ancient Egyptians knew of the disease, described it, and today we find evidences of it in the preserved bodies of their dead. Yet it is really only since the middle of the last century that physicians and scien- tists have studied cancer and its genesis in any real detail, and not until dte past quarter century that we have begun to understand the basic nature of the neoplastic cell. Cancer has been considered to be a disease of civiliza- tion. For the most part, the tribes of the earth that have not been touched (or contaminated) by civilization have a lower incidence of cancer. In animals that live in the wild cancer is a rarity, while the dog and the cat, in their gentle association with humans, exhibit a relatively high incidence of neoplastic disease. It has been claimed that more than 80% of cancers in humans ate caused by environmental factors. Substantial evidence has ac- cumulated that many of these environmental factors are chemicals resulting primarily from smoking and our diet, both iih amount and in quality. Today, the efforts of many scientists are directed towards preventing cancer by determining which specific chemicals in our envi- rotunent offer the greatest hazard to the public. While cancer is nat the only disease whose incidence appears to have increased as the industrial age expands, the preva- lence of this disease, coupled with the concern of the public, have made the study and conquest of cancer one of our major national priorities. For such studies we need individuals having an under- standing of cancer as a disease, in order that they may extend and utilize knowledge as it becomes available. The clinician, the pathologist, and the basic scientist can all contribute to this effort. The Damon Runyon-Walter Winchell Cancer Fund does not have the monetary base of the National Cancer Institute. Therefore, the decision of the Board of Direc- tors to utilize the limited financial resources of the Fund in the support of fellowships for postdoctoral training of the most promising talent in cancer research is the best way to make a little go a long way in our effort to conquer this disease; Let us all join in the effort, with the past, present, and future Damon Runyon-Walter Winchell Fel- lows, to insure that the gift of life is healthy, happy, and fruitful for all of us. Henry C. Pitot, M.D. Dr. Pitot, a member of the Board of Directors of the Rurn•on-Winchell Cancer Fund. is director of the McArdle 1-hboraton•forCancer Research in Madison. Wisconsin. Dr. Murphy (Contrmred fmm page 1) The clinical program at the Institute is organized by organ site, and emphasizes patient entry into investiga- tive studies. The staff is organized to facilitate organ site programs combining laboratory research, detection, treatment services, and education. Dr. Murphy has been extensively involved in both the treatment and investigatian of cancer throughout his career. He has had numerous professional appointments, including the National Cancer Institute, the American College of Surgeons, the American Cancer Society, and the International Union Against Cancer. Dr. Murphy has served on a variety of nationa: and state committees. commissions, and councils, and maintained active ties to the field of educahon. He has authored or co-authored mcre than 800 scientific publications and over twelve texts covering a broad spectrum of cancer, transplanta- tion, endocrinology, and urology. Dr. Murphy has been a member of the Board of Directors of the Runyon-Winchell Cancer Fund since 1979, and Chairman of the Board's Executive Commit- tee since 1980. He feels that the Fund has played an important role in cancer research since its inception, and will continue to expand its participation in the years to come. Dr. Murphy points out that indications are quite clear that the immediate future will bring breakthroughs in biology and physiology in many directions, which will, in turn, lead to accelerated efforts in many aspects of cancer research. The Fund is especially grateful for Dr. Murphy's leadership during this exciting and chal- lenging time. 5

t• - Runyon-Winchell Fellow - Class of 1949 In our last issue, we began a series which irill chroni- cle the scicntiftc achievements and careers of some of the first invesUr'gators supported by the Rurn•on-Winchell Cancer Fund. In this issue we profile Dr B. J. Kennedr. who was a jlunpon-Winchel! F'ellow from 1949-195l. Dr. Kennedy is currently Professor of Medicine. Masonic Professor of Oncology: and Director of Medical Oncol- ogy at the University of Minnesota Medical School and the Masonic Cancer Center in Minneapolis. Following resident training in internal medicine at the Massachusetts General Hospi- tal, I spent two years as a clini- cal cancer re- search fellow at Harvard Medi- cal School. While there I conducted studies on the hormonal treat- ment of cancer, metabolisnh, and the beginning of cytotoxic chemo- therapy, under the guidance of Drs. Joseph C. Aub and hm T. Nath'anson. In order to further develop my skills in endocrinology, two years of research were planned at the University Clinic of McGill Medical School under Dr. John S.L. Browne, and at the Endocrine Service of New York Hospital with Dr. Ephraim Shorr. I was awarded a tao year ~ellowship by the Runyon-Winchell Cancer A~nd~nrd949, which made it possible to plan this re- search program in advance and to further develop my skills in the metabolic aspects of cancer patients. As it became apparent to me that there was a real role for the internist to play in cancer research and the care of cancer patienu. I returned in 1952 to the University of Minnesota where I had attended college and medical school. As an Assistatit Professor of Medicina I directed the Endocrine Clinic and the Breast Section of the'Ihmur Clinic. A Metabolism Laboratory and Researeh Ward was established where I studied the hormonal treatment of breast cancer with respect to estrogens, androgens, and hypophysectomy. Although metabolic studies of calcium, phosphorus, and magnesium were em- phasized, the development of chemotherapy in a variety of neoplasms extended my interests and research to lymphomas, leukemia, testis cancer, and glioblastomas. In 1958 the Masons of Minnesota established the Masonic Memorial Hospital for the care of advanced cancer patients, where I directed the 40-bed medicine service. These patients provided the basis for the de- velopment of methods for patient care. cancer educa- tion, and clinical cancer research. Ten years later the facility was expanded, and most recently was designated the Masonic Cancer Center. It was during these years of professional development 6 that I realized there was a major role for internal medicine in the cancer program. The concept of the medical oncologist was developed, and I was instrumen- ta1 in 1972 in having the American Board of Medical Specialties recognize Medical Oncology as a subspe- cialty of Internal Medicine. I was appointed the first Chairman of the $ubcommittee for Medical Oncology of the American Bdar,d of Intemal Medicine, and helped define the scope of this new subspecialty. as well as establishing guidelines for training. The enermous im- pact that medical oncologists have had on the care of cancer patients and in cancer research and education is well recognized throughout this country and the world. In 19701 was named the Masonic Professor of Oncol- ogy. My research continued to emphasize breast and testis cancer, while, most recently I have seen and em- phasized the need for expanded research in the cancer problems of the elderly. As my own faculty has increased in number and perspective. I have participated in several new areas of tumor research. concentrating on develop- ing the careers of young persons. I feel that the Runyon-Winchell Cancer Fund's policy of -gr-anting fellowships to young scientists to help establish their scientific careers is a prudent and well-advised philoso- phy. The field of Medical Oncology involves many areas of cancer research and offers a rewarding career for those adequately trained.. The evolution of Medical Oncology has been an excit- ing experience for me. During this era, the development of chemotherapy has resulted in longer survival of pa- tients with cancer, and the cure of certain neoplasms. The award of a Rttnyon-Winchell Fellowship was essen- tial in the development of the flexible research program that enabled me to pursue and continue a career in my field, and helped me become a scientist, physician, and educator. Carolina Herrera.19S2 International Fashion Aa•ard Honoree. with Louis DeLuca, Executive Director qf the Runvon-Winc/aell Cancer Fund. Mrs. Herrera. tlre nored fashion designer, was presented with the award at a dinner in Los Angeles.